Agios Pharmaceuticals, Inc. (AGIO): R&D Expense
$339.54M
Year ended 2025-12-31
$356.75M
Trailing 12 months to 2026-06-30
+6.6%
3-year compound annual growth
+9.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $339.54M | +12.7% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $301.29M | +1.9% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $295.53M | +5.6% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $279.91M | +8.9% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $256.97M | +16.4% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $220.81M | +3.1% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $214.26M | n/c | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $341.32M | +16.6% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $292.68M | +32.9% | 2020-02-19, From 2017-01-01 |
| 2016-12-31 | $220.16M | +55.2% | 2019-02-14, From 2016-01-01 |
| 2015-12-31 | $141.83M | +41.3% | 2018-02-14, From 2015-01-01 |
| 2014-12-31 | $100.37M | +84.2% | 2017-02-16, From 2014-01-01 |
| 2013-12-31 | $54.50M | +32.8% | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | $41.04M | +31.3% | 2015-02-24, From 2012-01-01 |
| 2011-12-31 | $31.25M | n/a | 2014-03-18, From 2011-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $339.54M | +12.7% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.16M | -60.2% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $117.33M | -3.0% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $197.10M | +54.4% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $0 | -100.0% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $61.12M | -27.7% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Journey Medical Corp (DERM) | 2025-12-31 | $480.0K | -95.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $132.16M | -8.2% |
Compare AGIO, QTTB, NKTR, OCUL side by side · Screen every company in Pharmaceutical Preparations ↗